Does IPILIMUMAB Cause Immune-mediated myocarditis? 248 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 248 reports of Immune-mediated myocarditis have been filed in association with IPILIMUMAB (YERVOY). This represents 0.7% of all adverse event reports for IPILIMUMAB.
248
Reports of Immune-mediated myocarditis with IPILIMUMAB
0.7%
of all IPILIMUMAB reports
63
Deaths
162
Hospitalizations
How Dangerous Is Immune-mediated myocarditis From IPILIMUMAB?
Of the 248 reports, 63 (25.4%) resulted in death, 162 (65.3%) required hospitalization, and 88 (35.5%) were considered life-threatening.
Is Immune-mediated myocarditis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IPILIMUMAB. However, 248 reports have been filed with the FAERS database.
What Other Side Effects Does IPILIMUMAB Cause?
Death (3,710)
Malignant neoplasm progression (3,296)
Diarrhoea (2,557)
Off label use (2,097)
Colitis (1,988)
Pyrexia (1,796)
Rash (1,556)
Fatigue (1,447)
Intentional product use issue (1,329)
Nausea (1,169)
What Other Drugs Cause Immune-mediated myocarditis?
PEMBROLIZUMAB (599)
NIVOLUMAB (444)
CARBOPLATIN (93)
DURVALUMAB (74)
LENVATINIB (66)
DOXORUBICIN (59)
PACLITAXEL (58)
PEMETREXED (43)
ATEZOLIZUMAB (37)
BEVACIZUMAB (32)
Which IPILIMUMAB Alternatives Have Lower Immune-mediated myocarditis Risk?
IPILIMUMAB vs IPRAGLIFLOZIN L-PROLINE
IPILIMUMAB vs IPRATROPIUM
IPILIMUMAB vs IPRATROPIUM\IPRATROPIUM ANHYDROUS
IPILIMUMAB vs IPTACOPAN
IPILIMUMAB vs IRBESARTAN